Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1993 Apr;67(4):806–812. doi: 10.1038/bjc.1993.147

The clinical epidemiology of superficial bladder cancer. Dutch South-East Cooperative Urological Group.

L A Kiemeney 1, J A Witjes 1, A L Verbeek 1, R P Heijbroek 1, F M Debruyne 1
PMCID: PMC1968355  PMID: 8471440

Abstract

Even though the majority of patients with bladder malignancies initially present with low stage disease, the clinical epidemiology of these so-called superficial bladder tumours is not well known. In this paper, disease characteristics at initial presentation and during follow-up are described in 1,745 primary cases documented prospectively in the Netherlands. The risk of recurrent disease after primary treatment is very high: in 60% of cases, at least one recurrence is diagnosed within 5 years (95% CI: 58-62%). In patients with a small solitary pTa grade 1 tumour, the 3-year recurrence risk is 37%. In patients with multiple large high grade pT1 tumours, this risk is as high as 77%, despite a significant beneficial effect of adjuvant intravesical chemotherapy. The actuarial risk of disease progression is 10.2% after 3 years (95% CI: 8.6-11.8%). This risk of progression depends on the patient's age at diagnosis, tumour stage, grade, multiplicity and the presence of dysplasia or CIS in random urothelium biopsies. The use of intravesical instillations with chemotherapy or BCG vaccine after TUR does not prevent progressive disease, although this finding is difficult to interpret from a non-randomised study. The 5-year relative survival in patients with superficial TCC of the bladder is 86% (95% CI: 84-88%).

Full text

PDF
806

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abel P. D., Hall R. R., Williams G. Should pT1 transitional cell cancers of the bladder still be classified as superficial? Br J Urol. 1988 Sep;62(3):235–239. doi: 10.1111/j.1464-410x.1988.tb04325.x. [DOI] [PubMed] [Google Scholar]
  2. Abel P. D., Henderson D., Bennett M. K., Hall R. R., Williams G. Differing interpretations by pathologists of the pT category and grade of transitional cell cancer of the bladder. Br J Urol. 1988 Oct;62(4):339–342. doi: 10.1111/j.1464-410x.1988.tb04361.x. [DOI] [PubMed] [Google Scholar]
  3. Abel P. D. Prognostic indices in transitional cell carcinoma of the bladder. Br J Urol. 1988 Aug;62(2):103–109. doi: 10.1111/j.1464-410x.1988.tb04286.x. [DOI] [PubMed] [Google Scholar]
  4. Eure G. R., Cundiff M. R., Schellhammer P. F. Bacillus Calmette-Guerin therapy for high risk stage T1 superficial bladder cancer. J Urol. 1992 Feb;147(2):376–379. doi: 10.1016/s0022-5347(17)37241-5. [DOI] [PubMed] [Google Scholar]
  5. Flamm J., Dona S. The significance of bladder quadrant biopsies in patients with primary superficial bladder carcinoma. Eur Urol. 1989;16(2):81–85. doi: 10.1159/000471541. [DOI] [PubMed] [Google Scholar]
  6. Flamm J., Havelec L. Factors affecting survival in primary superficial bladder cancer. Eur Urol. 1990;17(2):113–118. doi: 10.1159/000464017. [DOI] [PubMed] [Google Scholar]
  7. Gulliford M. C., Petruckevitch A., Burney P. G. Survival with bladder cancer, evaluation of delay in treatment, type of surgeon, and modality of treatment. BMJ. 1991 Aug 24;303(6800):437–440. doi: 10.1136/bmj.303.6800.437. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Heney N. M., Ahmed S., Flanagan M. J., Frable W., Corder M. P., Hafermann M. D., Hawkins I. R. Superficial bladder cancer: progression and recurrence. J Urol. 1983 Dec;130(6):1083–1086. doi: 10.1016/s0022-5347(17)51695-x. [DOI] [PubMed] [Google Scholar]
  9. Heney N. M. Intravesical chemotherapy: how effective is it? Urology. 1988 Mar;31(3 Suppl):17–19. [PubMed] [Google Scholar]
  10. Herr H. W., Laudone V. P., Badalament R. A., Oettgen H. F., Sogani P. C., Freedman B. D., Melamed M. R., Whitmore W. F., Jr Bacillus Calmette-Guérin therapy alters the progression of superficial bladder cancer. J Clin Oncol. 1988 Sep;6(9):1450–1455. doi: 10.1200/JCO.1988.6.9.1450. [DOI] [PubMed] [Google Scholar]
  11. Herr H. W. Transurethral resection and intravesical therapy of superficial bladder tumors. Urol Clin North Am. 1991 Aug;18(3):525–528. [PubMed] [Google Scholar]
  12. Jordan A. M., Weingarten J., Murphy W. M. Transitional cell neoplasms of the urinary bladder. Can biologic potential be predicted from histologic grading? Cancer. 1987 Dec 1;60(11):2766–2774. doi: 10.1002/1097-0142(19871201)60:11<2766::aid-cncr2820601129>3.0.co;2-0. [DOI] [PubMed] [Google Scholar]
  13. Levine M. N., Browman G. P., Gent M., Roberts R., Goodyear M. When is a prognostic factor useful? A guide for the perplexed. J Clin Oncol. 1991 Feb;9(2):348–356. doi: 10.1200/JCO.1991.9.2.348. [DOI] [PubMed] [Google Scholar]
  14. Lum B. L., Torti F. M. Adjuvant intravesicular pharmacotherapy for superficial bladder cancer. J Natl Cancer Inst. 1991 May 15;83(10):682–694. doi: 10.1093/jnci/83.10.682. [DOI] [PubMed] [Google Scholar]
  15. Newling D. Intravesical therapy in the management of superficial transitional cell carcinoma of the bladder: the experience of the EORTC GU Group. Br J Cancer. 1990 Apr;61(4):497–499. doi: 10.1038/bjc.1990.112. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Parmar M. K., Freedman L. S., Hargreave T. B., Tolley D. A. Prognostic factors for recurrence and followup policies in the treatment of superficial bladder cancer: report from the British Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party). J Urol. 1989 Aug;142(2 Pt 1):284–288. doi: 10.1016/s0022-5347(17)38731-1. [DOI] [PubMed] [Google Scholar]
  17. Pauwels R. P., Schapers R. F., Smeets A. W., Debruyne F. M., Geraedts J. P. Grading in superficial bladder cancer. (1). Morphological criteria. Br J Urol. 1988 Feb;61(2):129–134. doi: 10.1111/j.1464-410x.1988.tb05060.x. [DOI] [PubMed] [Google Scholar]
  18. Pocock R. D., Ponder B. A., O'Sullivan J. P., Ibrahim S. K., Easton D. F., Shearer R. J. Prognostic factors in non-infiltrating carcinoma of the bladder: a preliminary report. Br J Urol. 1982 Dec;54(6):711–715. doi: 10.1111/j.1464-410x.1982.tb13631.x. [DOI] [PubMed] [Google Scholar]
  19. Richards B., Parmar M. K., Anderson C. K., Ansell I. D., Grigor K., Hall R. R., Morley A. R., Mostofi F. K., Risdon R. A., Uscinska B. M. Interpretation of biopsies of "normal" urothelium in patients with superficial bladder cancer. MRC Superficial Bladder Cancer Sub Group. Br J Urol. 1991 Apr;67(4):369–375. doi: 10.1111/j.1464-410x.1991.tb15164.x. [DOI] [PubMed] [Google Scholar]
  20. Schouten L. J., van den Brandt P. A., Jager J. J. Cancer incidence in the province of Limburg, The Netherlands. Eur J Cancer. 1992;28A(10):1752–1755. doi: 10.1016/0959-8049(92)90083-e. [DOI] [PubMed] [Google Scholar]
  21. Soloway M. S., Murphy W. M., Johnson D. E., Farrow G. M., Paulson D. F., Garnick M. B. Initial evaluation and response criteria for patients with superficial bladder cancer. Report of a workshop. Br J Urol. 1990 Oct;66(4):380–385. doi: 10.1111/j.1464-410x.1990.tb14958.x. [DOI] [PubMed] [Google Scholar]
  22. Solsona E., Iborra I., Ricós J. V., Monrós J. L., Dumont R., Casanova J., Calabuig C. Carcinoma in situ associated with superficial bladder tumor. Eur Urol. 1991;19(2):93–96. doi: 10.1159/000473592. [DOI] [PubMed] [Google Scholar]
  23. Vögeli T., Ackermann R. When does superficial bladder cancer resist intravesical therapy? Semin Urol. 1990 Nov;8(4):248–253. [PubMed] [Google Scholar]
  24. Wolf H., Olsen P. R., Fischer A., Højgaard K. Urothelial atypia concomitant with primary bladder tumour. Incidence in a consecutive series of 500 unselected patients. Scand J Urol Nephrol. 1987;21(1):33–38. doi: 10.3109/00365598709180287. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES